Voyager Therapeutics (FRA:VT6) Institutional Ownership: 23.18% (As of Jul. 11, 2026)


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
52 GF Score
Price €3.06
GF Value €1.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Institutional Ownership?

Voyager Therapeutics FRA:VT6 -2.05% 52 Institutional Ownership is 23.18% as of Jul. 11, 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 52/100 and a GF Value™ of €1.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Voyager Therapeutics's institutional ownership is 23.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Voyager Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Voyager Therapeutics's Float Percentage Of Total Shares Outstanding is 85.17%.

Voyager Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Institutional Ownership Chart

Voyager Therapeutics Historical Data

The historical data trend for Voyager Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 27.14 27.14 27.06 25.79 25.27 24.71 23.45 23.13 22.50 23.18
FRA:VT6
52GF Score
Voyager Therapeutics Inc FRA:VT6
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.18% mean?
Voyager Therapeutics (FRA:VT6) has a Institutional Ownership of 23.18% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Institutional Ownership too high?
Voyager Therapeutics' current Institutional Ownership is 23.18%. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Institutional Ownership compare to KROS and CDXS?
Voyager Therapeutics' Institutional Ownership of 23.18% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Institutional Ownership is 23.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €3.06 — trading 116.7% above its estimated fair value. The current Institutional Ownership is 23.18%. Voyager Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Institutional Ownership is 23.18% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.06 is trading 116.7% above its estimated GF Value™ of €1.41. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Institutional Ownership: 23.18%
  • GF Value™: €1.41 vs. price of €3.06 (116.7% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for FRA:VT6

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€1.41
GF Value